Lataa...
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia
BACKGROUND: Imatinib, a first-generation tyrosine kinase inhibitor (TKI), and the newer second-generation TKIs have dramatically improved outcomes for patients with chronic myelogenous leukemia (CML). A previous model estimated the potential cost-savings over the next 2 years after the loss of paten...
Tallennettuna:
| Julkaisussa: | Am Health Drug Benefits |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Engage Healthcare Communications, LLC
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6996618/ https://ncbi.nlm.nih.gov/pubmed/32055281 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|